Know2eat

Boswellia

Boswellia serrata

Herbs & Botanicals

What boswellia may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedJoint comfortLimited evidence· 2 sources

Then, in order

4 things to know first — allergies, interactions and limits

About Boswellia

A gum resin extract from the Boswellia tree, standardised to boswellic acids — most often the acetyl-11-keto-beta-boswellic acid fraction, abbreviated AKBA.

Boswellia has a moderately encouraging small-trial literature in osteoarthritis, with most studies running 8 to 12 weeks in Indian centres and several funded by the manufacturers of branded resin extracts. The clinically relevant fraction, AKBA, makes up only a few percent of ordinary gum resin, so products differ substantially in what they actually deliver.

Sold as
Standardised resin extract capsule, AKBA-enriched extract, Tablet, Topical cream
Standardised to
Commonly 30–65% boswellic acids, or stated AKBA percentage — a product without this marker may not resemble what was studied.
Also known as
Indian frankincense, Salai guggul, Shallaki

What the research used

The amounts, forms and durations published trials of Boswellia actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Knee osteoarthritis

    100–1000 mg

    Limited

    Standardised resin extract, divided doses · Trials range from 30% boswellic acids to AKBA-enriched preparations · 4–12 weeks

    The ten-fold dose range across trials reflects enrichment: 100 mg of an AKBA-enriched extract was tested against 1,000 mg of an ordinary one. Most of these trials were manufacturer-supported.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.

  • With food

    Limited

    Boswellic acids are lipophilic and absorption has been reported to increase with a fatty meal. Outcome trials did not compare fed and fasted dosing.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Limited

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Joint comfort

Joint Health
Limited evidence

Some randomised trials report reduced pain and stiffness in knee osteoarthritis over 4 to 12 weeks. The trials are small, concentrated in a few centres, frequently industry-funded, and use extracts that are not interchangeable.

What may be going on: Boswellic acids inhibit 5-lipoxygenase and leukotriene synthesis in laboratory models.

Limited evidence. Early human work, or mostly lab and animal research.

View the 2 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Digestive comfort

Gut & Digestive Health
Not enough evidence

Evidence is limited for boswellia in inflammatory bowel conditions. Early trials suggested promise but a larger controlled trial in Crohn’s disease found no advantage over placebo.

Not enough evidence. Not enough human research to say anything useful yet.

No source is attached to this association yet, so it is rated not enough evidenceby default. It is listed because people commonly ask about it — not because there is evidence for it.

Inflammatory markers

Inflammation
Not enough evidence

There is not enough human research to say boswellia changes circulating inflammatory markers. Most of the mechanistic work is in cells and animals.

Not enough evidence. Not enough human research to say anything useful yet.

View the 4 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Worth knowing

    Digestive upset is the usual complaint

    Nausea, acid reflux and diarrhoea are the most frequently reported effects, and are more common at the higher end of trial doses.

  • Interaction

    Possible interaction with drug metabolism and anticoagulants

    Interacts withWarfarin, antiplatelet drugs, CYP3A4 substrates

    Boswellic acids inhibit CYP enzymes in laboratory work and may add to antiplatelet effects, so combinations with warfarin, aspirin or narrow-margin medicines deserve a prescriber conversation.

  • Avoid

    Pregnancy

    Boswellia has traditional emmenagogue use and no pregnancy safety data. It is generally avoided in pregnancy and breastfeeding.

  • Worth knowing

    Species and resin adulteration

    Boswellia serrata, sacra, carterii and papyrifera are different species with different acid profiles, and resin is a commodity with documented adulteration. Boswellic acid content on a label is often unverified.

Evidence ratings on this page: 1 limited evidence, 2 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Boswellia, or a dose to follow.